Updated Use Instructions for Maquet Servo Ventilator Systems

Risk in Neonatal Tidal Volume Delivery
Servo ventilation systems

Maquet Servo Ventilator Systems
Source: FDA

Urgent Class I Medical Device Correction

Maquet Critical Care AB, a subsidiary of Getinge, has issued an urgent correction notice regarding its Servo Ventilator Systems (Servo-u, Servo-n, and Servo-u MR). This correction does not involve product removal, but the FDA has classified it as a Class I recall, the most serious type, due to the potential risk of injury or death if devices are used incorrectly.

Device Overview

These ventilators are used in professional healthcare settings for neonatal, pediatric, and adult patients, including in MR environments (Servo-u MR only). The devices assist or control breathing by delivering oxygen-rich air at controlled volumes.

Issue Summary

Maquet has updated its user instructions after discovering that incorrect configuration of the “Extended leakage test” could cause inaccurate compliance measurements, especially dangerous for neonatal patients. This could result in improper tidal volume delivery:

  • In PRVC mode, up to 50% less tidal volume may be delivered than displayed.
  • In Pressure Control mode, displayed tidal volume may appear higher than what is delivered.

Health Risks

Improper tidal volume delivery may cause hypoventilation, hypoxia, or hypercapnia, particularly in extremely premature neonates. One injury has been reported, with no deaths to date.

Recommended Actions

Issued on May 30, 2025, the correction letter advises:

  • Set the “Extended leakage test” to OFF unless using a compatible humidifier (see User Manual, Chapter 8.2.4).
  • Follow revised safety check instructions in Appendix 1, Chapter 9.5.1 of the user’s manual.
  • Notify all affected personnel and verify all ventilators are properly configured.

Contact Info

For technical assistance, U.S. customers can reach Maquet Technical Services at 1-888-943-8872 (Option 4), weekdays 8:00 a.m. to 6:00 p.m. ET.

Read the original medical device alert here.

FDA Approves XACT Carotid Stent System

A Breakthrough for Stroke Prevention  Abbott Vascular Inc. has received FDA approval for its groundbreaking XACT Carotid Stent System, a significant advancement in stroke prevention technology. Approved on February 7, 2024, this innovative system offers new hope for...

FDA’s Orphan Drug Program

Expedite Development of New Orphan Drugs  The FDA's Orphan Drug Program is designed to encourage the development of drugs and biologics for the treatment, diagnosis, or prevention of rare diseases or conditions, often referred to as orphan diseases. Here are the key...